Recent Posts in ‘Biotech Stock Profiles’
Cardium (CXM) Initiates Generx(R) Phase 3 Clinical Registration Study
Cardium Therapeutics (NYSE Amex: CXM), a health sciences and regenerative company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), recently announced
Pressure BioSciences (PBIO): How Much is It Really Worth?
Pressure BioSciences Inc. (NASDAQ: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN), appears to be significantly undervalued by the market. Significant Growth Potential Ahead Pressure BioSciences is preparing to commercialize
Pressure BioSciences (PBIO): Highly Misunderstood, Significantly Undervalued
Pressure BioSciences Inc. (NASDAQ: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen, Inc. (NASDAQ: AMGN), is a highly misunderstood and significantly undervalued stock. Pressure BioSciences’ Three Big Misunderstandings Investors face three key fears
Pressure BioSciences (PBIO): A Game-Changing Technology Platform
Pressure BioSciences Inc. (NASDAQ: PBIO) is a developer of proprietary laboratory instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), competing against other companies in the sample preparation technology sector, like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX). Simplifying and Improving Sample Preparation Lab sample preparation is often
Senesco (SNT): A Unique Approach to Treating Disease
Senesco Technologies Inc. (AMEX: SNT) is a development-stage biotechnology company with a proprietary technology that regulates programmed cell death (apoptosis), working in the areas of oncology and rheumatology alongside larger competitors like Dendreon Corporation (NASDAQ: DNDN), Merck & Co., Inc. (NYSE: MRK) and many others. Initially, the company’s unique technology was developed for agricultural applications
ImmunoCellular (IMUC) Shareholder Update Validates Strong Potential for Growth
Biotechnology topics are hot in the investment community. Acquisitions are regularly being reported, new treatments are advancing in cancer therapy and stem cell research is being pursued down multiple avenues for its core competencies of repairing damaged body parts at the root of the problem. Bringing together these topics points to the direction of ImmunoCellular
Galectin Therapeutics (GALT): Three Franchises, One Big Opportunity
Galectin Therapeutics Inc. (OTCBB: GALT) is a leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins involved in progression or cause of disease. The promising role of galectin in cancer could give the company a distinct position with hopes of synergizing with other companies fighting cancer, from Dendreon Corporation (NASDAQ: DNDN) to Generex Biotechnology
ImmunoCellular (IMUC) Accelerating ICT-107 Clinical Trial Enrollment for Glioblastoma
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike other cancer treatment companies, such as Dendreon (NASDAQ: DNDN), Oncothyreon (NASDAQ: ONTY) , IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer
Amarantus (AMBS) CEO Gerald Commissiong Featured in Interview
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Cardium (CXM) Inks First Marketing & Distribution Agreement for Excellagen(TM)
Cardium Therapeutics (Amex: CXM), a developer and acquirer of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), recently entered into first marketing and distribution agreement
Amarantus (AMBS) Updates Shareholders on Expanded Corporate Strategy
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Cardium (CXM) and SourceOne Global Partners in Nutritional Supplement and Medical Foods Market
Cardium Therapeutics (NYSE Amex: CXM), a developer and acquirer of innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Nutraceutical International Corp (NASDAQ: NUTR) and Schiff Nutrition International Inc. (NYSE: WNI), recently partnered up with SourceOne via cross strategic investment